<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung DiseasePierre‐Antoine Juge, Annick Clément, Naoyuki Tsuchiya et al.|New England Journal of Medicine|2018Cited by 501
Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial DiseaseAlida L.P. Caforio, Aleš Linhart, Yehuda Adler et al.|European Heart Journal|2017Cited by 263
Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosisNadira Ruzehaji, Yannick Allanore|Annals of the Rheumatic Diseases|2016Cited by 96
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cellsJ. Distler, Oliver Distler, Yannick Allanore et al.|Annals of the Rheumatic Diseases|2008Cited by 94
Driving Role of Interleukin‐2–Related Regulatory <scp>CD4</scp>+ T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic SclerosisC. Frantz, Yannick Allanore, Anne Cauvet et al.|Arthritis & Rheumatology|2022Cited by 22